CAJ | 학술논문

目的：观察米托蒽醌联合阿糖胞苷及门冬酰胺酶方案对CD7+急性髓系白血病诱导治疗的疗效。方法2008年10月-2013年1月我院收治的原发初治患者CD7+AML21例，予米托蒽醌联合阿糖胞苷及左旋门冬酰胺酶方案进行诱导化疗：米托蒽醌(MTZ)10mg/d，d1-3；阿糖胞苷(Ara-C)200mg/d，d1-7；左旋门冬酰胺酶(L-ASP)10000U/d，qod d8-26。结果21例患者13例获得完全缓解(CR 62%)，3例获得部分缓解(PR 14%)，有效率76%。结论米托蒽醌联合阿糖胞苷及门冬酰胺酶方案作为CD7+急性髓系白血病的诱导化疗方案，疗效尚可，值得进一步研究。
목적：관찰미탁은곤연합아당포감급문동선알매방안대CD7+급성수계백혈병유도치료적료효。방법2008년10월-2013년1월아원수치적원발초치환자CD7+AML21례，여미탁은곤연합아당포감급좌선문동선알매방안진행유도화료：미탁은곤(MTZ)10mg/d，d1-3；아당포감(Ara-C)200mg/d，d1-7；좌선문동선알매(L-ASP)10000U/d，qod d8-26。결과21례환자13례획득완전완해(CR 62%)，3례획득부분완해(PR 14%)，유효솔76%。결론미탁은곤연합아당포감급문동선알매방안작위CD7+급성수계백혈병적유도화료방안，료효상가，치득진일보연구。
Objective To obersive the effect of remission-inducing regimen on CD7+ acute myeloid leukemia(AML) using mitoxantrone combined with aclarubicin and asparaginase. Methods 21 patients with CD7+ AML were treated with mitoxantrone combined with aclarubicin and asparaginase: mitoxantrone 10mg/d, d1-3; cytarabine 200mg/d, d1-7;asparaginase 10000U, qod d8-26. Results The complete remission rate was 62%; the response rate was 76%. Conclusion Patients may benefit from itoxantrone combined with aclarubicin and asparaginase which would be pay more attention.